Navigation Links
Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics
Date:10/28/2008

GAITHERSBURG, Md., Oct. 28 /PRNewswire/ -- Sirnaomics, Inc. (http://www.sirnaomics.com) announced today that the company has received an SBIR (small business innovation research) grant from National Cancer Institute (NCI), National Institute of Health (NIH). Sirnaomics, Inc., a biopharmaceutical company founded in early 2007, is dedicated to advancing RNA interference (RNAi) Technology for novel targeted therapeutic development. The company's multi-targeted siRNA therapeutic programs utilizing its nanoparticle-enhanced delivery technologies represent a unique approach for truly realizing the advantages of small interfering RNA (siRNA)-based drugs to treat various critical human diseases. Sirnaomics has successfully attracted grants and investments from the State of Maryland (Department of Business and Economics Development -- DBED), Maryland Industrial Partnerships (MIPS) and Montgomery County Technology Growth Programs (TGP), in addition to the State of Maryland Tax Credit Program for Biotechnology Investment.

RNAi has emerged as a fundamentally important biological phenomenon and as a versatile, powerful tool for biomedical research. RNAi plays a multifaceted role in molecular biology by silencing genes through chromatin remodeling, interfering with protein synthesis, and in its best-studied mode of action quashing gene expression by cleaving messenger RNA. Experimental applications of RNAi have spurred the exploration of gene function in many basic research, drug discovery and clinical settings. The 2006 Nobel Prize for medicine and physiology and a number of corporate acquisitions and investments by Novartis, Merck, AstraZeneca, Roche and Takeda have injected billions of dollars into this novel technology and further fueled the enthusiasm for the great promise of siRNA therapeutics development.

Sirnaomics' mission is to advance RNAi technology by using its proprietary multi-targeted siRNA cocktail design together with the company's nanoparticle- mediated siRNA delivery vehicles in the rapid delivery of novel therapeutics. The company is dedicated to becoming the leader in the field of RNAi technology and its strong ties with biopharmaceutical communities in Asia (China) will allow the company to speed up its pre-clinical and clinical processes for novel siRNA therapeutic development at reduced cost. The company's proprietary "Tri-Blocker" technology for multi-targeted siRNA cocktail design and "Snano" series of nanoparticle delivery systems enable its advanced RNAi therapeutic programs for treatment of various critical human conditions including ocular diseases, viral infections, scarless wound repair and cancer.

"Receiving an SBIR grant from NCI further validates the scientific and business merits of our cancer therapeutic program using multi-targeted siRNA cocktails," said the founder, President and CEO of the company, also the Principle Investigator of the grant proposal, Dr. Patrick Y. Lu. "It is a successful extension of Sirnaomics product pipeline for siRNA therapeutics including the programs for ocular diseases, respiratory infectious diseases and scarless wound healing in their late stage of pre-clinical development." Dr. Lu further emphasized that the grants from various Government agencies provide a sustainable funding resource to the company in addition to its corporate partnership deals and venture capital investments. "Funding from Government is uniquely important for an early stage company like Sirnaomics, especially in the current financial environment."

Sirnaomics, Inc. is a privately held Delaware corporation headquartered in Gaithersburg, Maryland, USA. Established by a group of leading scientists in the field of RNAi technology, the company has the mission of advancing RNAi technology for novel drug discovery and targeted therapeutics development. After completing a pre-IND meeting with the FDA earlier this year, its leading siRNA therapeutic product, STP601, is expected to enter the clinic in 2009. Members of the senior management team bring over 50 years of combined experience in the biopharmaceutical, financial and business management industries and will ensure the healthy growth of Sirnaomics as an international biopharmaceutical enterprise.

Contact:

George J. Ji, MBA

Sirnaomics, Inc.

401 Professional Drive, Suite 130

Gaithersburg, MD 20879, USA

301-740-1730 Phone

301-740-1731 FAX

info-office@sirnaomics.com

http://www.sirnaomics.com


'/>"/>
SOURCE Sirnaomics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products
2. Sirnaomics Received Multiple Government Fundings For Its Multi-Targeted siRNA Therapeutics Programs
3. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
4. GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology
5. Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period
6. Alfacell Receives Going Concern Audit Opinion
7. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
8. NanoVibronix Receives FDA Clearance for its PainShield(TM) MD Device
9. PAREXEL Corporate Vice President Dr. Alberto Grignolo Receives Lifetime Achievement Award From Good Clinical Practice Journal
10. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
11. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... ... June 22, 2016 , ... Quantitative ... business incubator and current participant in the Phase 1 Ventures program, is leveraging ... , Quantitative Radiology Solutions helps physicians make better treatment decisions by quantifying ...
(Date:6/22/2016)... (PRWEB) , ... June 21, 2016 , ... New light-based ... cutting into the tissue — promise to enable both compact, wearable devices for point-of-care ... even deeper under the skin. , Recent work and visionary future directions are detailed ...
(Date:6/22/2016)... SAN DIEGO , June 22, 2016 /PRNewswire/ ... that has developed a testing platform designed specifically ... the formation of their scientific advisory board (SAB). ... of directors, the SAB is chartered to advise ... infectious disease assay platform. Led by Dr. ...
(Date:6/22/2016)... June 22, 2016 On Tuesday, June ... 4,843.76, up 0.14%; the Dow Jones Industrial Average advanced 0.14% ... 2,088.90, up 0.27%. The gains were broad based as five ... has initiated coverage on the following equities: Minerva Neurosciences Inc. ... PTLA ), Trevena Inc. (NASDAQ: TRVN ), ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
Breaking Biology News(10 mins):